Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. - Wikidata - awgldk - TriplyDB

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

http://www.wikidata.org/entity/Q33770207

about

The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL c Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes.First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab.The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.The spectrum of use of rituximab in chronic lymphocytic leukemia Role of rituximab in first-line treatment of chronic lymphocytic leukemia.Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Choosing first-line therapy for chronic lymphocytic leukemia.Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis.Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL).Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates.Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation Role of CD20 monoclonal antibodies in previously untreated chronic lymphocytic leukemia.Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach.Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia.A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention.Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.Understanding and circumventing resistance to anticancer monoclonal antibodies.New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents.What is the best frontline therapy for patients with CLL and 17p deletion?Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies.Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?Rituximab: current status as therapy for malignant and benign hematologic disorders.What do we do with chronic lymphocytic leukemia with 17p deletion?B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.An update on current and prospective immunotherapies for chronic lymphocytic leukemia.Cholorambucil versus Cholorambucil Plus Prednisolone as First-Line Therapy of Chronic Lymphocytic Leukemia in West of Iran.Rituximab for the treatment of patients with chronic lymphocytic leukemia The emerging therapeutic role of antibody mixtures.Applications of monoclonal antibodies for the treatment of hematological malignancies

P2860

Q24617708-989BEB33-D188-44BC-B870-D570016CFDE0 Q30356145-F259B52A-3438-4726-B29F-1895E6EFE769 Q30408922-5927A04B-2FE5-4516-B5C4-A7FDAC6056A6 Q33396222-8139C1F0-7091-4BAD-8112-BA57BBE93FAE Q33414468-94E77D7F-6D7A-4E35-BCCF-8528E5C45CD7 Q33956034-52E21376-54D7-41F6-9EB8-7040B5EA00F4 Q34310845-17CCE3A1-36EC-4F07-8A1F-FB090CE63193 Q34510030-441A3595-A957-4CB6-B070-DCC5ECB6466D Q34574147-9D1639B9-9C11-4EC7-83EA-3946DB4EA3FD Q34625543-BC9CF283-D5A9-4BD6-9AC0-EA342C7B33E8 Q35124844-8CB563AF-466F-40E1-8C32-3491A77B39DD Q35569491-9E7BA745-D943-47A6-A17C-FF4131D9C528 Q35613669-00B6AF4B-781D-400A-A0EE-D548233FB820 Q35683808-BEBAA715-47AB-4A8D-9BC6-E407AA1CD734 Q35766117-A488A6E4-A86C-4655-A127-64BD8D12859A Q36070219-6DB932E6-F91D-4C1D-B275-8685A1AD3F77 Q36182299-AAE26B6B-E31D-4915-81F3-E4ACD0842BF7 Q36218799-A238FC69-5A54-4413-81CF-947FC21A6428 Q36251887-39A35209-E4AF-40E7-8DE8-83D41776001C Q36423833-3DA6BFEC-AF14-4A7D-870D-EF8D75677DB7 Q36725445-BB4FA812-AFF8-4AA2-A473-0BAA8B0C273F Q36892621-3E04F91B-AE07-4E18-8BB3-C86BBD7D1491 Q37448352-4A7A51BA-012F-45E9-89A1-CC01FD1CA69F Q37559275-01F72896-B5C1-42D1-90A6-63256FBDE906 Q37672125-C68F6ED6-8419-4550-BD6B-C4E64AFE0B0B Q37767703-FC380F98-FE7B-442D-B119-488D801CCB6D Q37820433-0615B3A7-77E9-4666-AD46-A88495511005 Q37842484-5220E0ED-4B90-4982-8B63-27F683553F37 Q37975154-1FBDEC6B-B996-4131-8C68-40E33E646E34 Q37984551-CFC02968-59CA-4541-99D6-C5564AB8DB87 Q38063170-33987907-901C-41A5-9A7A-044CED804DE6 Q38124119-7815C449-B4FB-43C4-8704-C3EBD816ACD7 Q38445357-C5378884-02BE-4470-BC15-B2C26F6768E1 Q39994604-A8F13100-DDA9-4D3B-817A-385DD6E40DBD Q41241909-A844E626-7F50-43A3-838B-589FECDC6CBF Q46026271-34061FA0-9FFA-497E-98C9-5104A325B7DB Q57904664-B2F40D87-FEE7-4526-B951-ED597C6B68E9

P2860

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

http://www.wikidata.org/entity/Q33770207

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

@ast

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

@en

type

label

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

@ast

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

@en

prefLabel

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

@ast

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

@en

P1433

Q33770207-4765C269-0950-4C3D-90A8-EA7BDC3883B0

P1476

Q33770207-9011039D-3521-464F-A640-3A661CD9AFA9

P2093

Q33770207-0DC9D160-4979-4CA1-9FD7-D0A9A20BEBCD

Q33770207-47C396B0-2F6E-4A94-9B3B-40CC67D58B0B

Q33770207-8F2A73C0-0F34-46B1-A3A4-61BEE647621F

Q33770207-ACE4D635-BA5D-4E71-8768-4E4FDA9022C6

Q33770207-B6D86937-07D5-48C4-971F-B7FBBFB518C7

Q33770207-C8448D3C-D835-40BC-84CE-FDF80B1ED828

Q33770207-E0C60F79-A559-4A90-86F5-A90A710B6518

Q33770207-ED5FA1CA-2985-4FE5-ACFA-7F5FA2C94AF7

Q33770207-EFFD6B21-3407-474A-B84E-4E5860D4DE28

Q33770207-F454B5D0-003B-4C19-9557-360844395D90

P2860

Q33770207-12896480-2F37-4D5C-95B7-E782EE6791EE

Q33770207-32EB2333-A980-41B4-99B0-A482F5043F88

Q33770207-3FCB1C2E-DCAE-4DB3-9CFD-BC7F84DCB5EC

Q33770207-43359A3D-2341-4031-91BE-CBFF1BA89BBE

Q33770207-4D1F3113-9AB2-49C5-9E4C-43DE807E6804

Q33770207-551F95EB-8D43-4A60-8537-A2FABE59C82E

Q33770207-5665301F-51CF-44F4-AB85-92B79D1C5D3A

Q33770207-5D05D526-0AF4-46E2-B7C5-D8FA8C062F77

Q33770207-64E578AD-2E35-4635-B7FC-DD98FC6B88E1

Q33770207-67698CC3-5A59-40B2-BC26-A211304F29E3

P304

Q33770207-8BE3A025-285E-41F6-A727-1AE8E34293C5

P31

Q33770207-3809A140-FBD4-491F-8F77-8D354FFB2044

P356

Q33770207-72F8C27A-E516-4C0D-9CB1-EEECB1A55453

P407

Q33770207-521AF121-0D89-4358-887C-CD438F1F8588

P433

Q33770207-48034D6D-A9B2-476D-8DE6-EDF64C9F4F0B

P478

Q33770207-9247066B-2E9E-4E03-AE49-D2B7FB5E5DC9

P577

Q33770207-F2972C79-C7CA-44D8-83E4-F14C0E67EC39

P5875

Q33770207-83B0CE07-11F4-4983-B5EA-3A03EA0E3B53

P698

Q33770207-543A1E0E-A8C7-4E6F-AAE2-B1FFF4D63658

P921

Q33770207-0D737130-47C5-4DF3-A224-ADDF621D6BBC

Q33770207-933704D2-80F5-448F-ADA5-C7F722AB3BA1

P932

Q33770207-DEB1B89B-CB2E-4469-97A4-A142EF7F2C48

P356

P1433

P1476

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

@en

P2093

Betsy R Laplant

http://www.w3.org/2001/XMLSchema#string

Brian F Kabat

http://www.w3.org/2001/XMLSchema#string

Charla R Secreto

http://www.w3.org/2001/XMLSchema#string

Clive S Zent

http://www.w3.org/2001/XMLSchema#string

Deborah A Bowen

http://www.w3.org/2001/XMLSchema#string

Diane F Jelinek

http://www.w3.org/2001/XMLSchema#string

Neil E Kay

http://www.w3.org/2001/XMLSchema#string

Renee C Tschumper

http://www.w3.org/2001/XMLSchema#string

Tait D Shanafelt

http://www.w3.org/2001/XMLSchema#string

Timothy G Call

http://www.w3.org/2001/XMLSchema#string

P2860

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Genomic aberrations and survival in chronic lymphocytic leukemia

Clinical staging of chronic lymphocytic leukemia.

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

P304

2110-2118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.23824

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23225573

http://www.w3.org/2001/XMLSchema#string

P698

18759253

http://www.w3.org/2001/XMLSchema#string

P921

P932

2849723

http://www.w3.org/2001/XMLSchema#string